Next-generation malaria subunit vaccines to reduce disease burden in African children

Affiliations

¹ Swiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland; University of Basel, Switzerland, Basel, Switzerland. Electronic address: claudia.daubenberger@swisstph.ch.
² ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain.

Comment

Claudia A Daubenberger et al. Lancet Infect Dis. 2022 Dec.

. 2022 Dec;22(12):1655-1656.

doi: 10.1016/S1473-3099(22)00523-0. Epub 2022 Sep 7.

¹ Swiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland; University of Basel, Switzerland, Basel, Switzerland. Electronic address: claudia.daubenberger@swisstph.ch.
² ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain.

No abstract available

Conflict of interest statement

We declare no competing interests.

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Datoo MS, Natama HM, Somé A, Bellamy D, Traoré O, Rouamba T, Tahita MC, Ido NFA, Yameogo P, Valia D, Millogo A, Ouedraogo F, Soma R, Sawadogo S, Sorgho F, Derra K, Rouamba E, Ramos-Lopez F, Cairns M, Provstgaard-Morys S, Aboagye J, Lawrie A, Roberts R, Valéa I, Sorgho H, Williams N, Glenn G, Fries L, Reimer J, Ewer KJ, Shaligram U, Hill AVS, Tinto H. Datoo MS, et al. Lancet Infect Dis. 2022 Dec;22(12):1728-1736. doi: 10.1016/S1473-3099(22)00442-X. Epub 2022 Sep 7. Lancet Infect Dis. 2022. PMID: 36087586 Clinical Trial.